PhoenixBio Co., Ltd. secured publication of European patent application EP4039797A1 for human fatty liver model cells, classified under IPC C12N 5/071 and A01K 67/027. The application covers biological materials and methods for modeling fatty liver disease, designated across 31 European states including all EU member states.\n\nPharmaceutical and biotechnology companies engaged in metabolic disease research, drug development for fatty liver conditions, or hepatotoxicity testing should conduct freedom-to-operate analyses to assess potential infringement risks. No immediate compliance action is required, but proactive IP due diligence is recommended before commercializing related products.